A large trial established the favorable clinical profile of a new polymer-free biolimus-A9-eluting stent (PF-BES) with a 1-month dual antiplatelet therapy (DAPT) regimen in patients at high bleeding risk (HBR). We evaluated the real-world patterns of indications, DAPT strategies and outcomes for the PF-BES following this evidence.
Dual antiplatelet therapy strategies and clinical outcomes for a polymer-free biolimus A9-coated stent
D'Ascenzo, Fabrizio
First
;Gallone, Guglielmo;Boccuzzi, Giacomo;Infantino, Vincenzo;De Ferrari, Gaetano Maria;
2019-01-01
Abstract
A large trial established the favorable clinical profile of a new polymer-free biolimus-A9-eluting stent (PF-BES) with a 1-month dual antiplatelet therapy (DAPT) regimen in patients at high bleeding risk (HBR). We evaluated the real-world patterns of indications, DAPT strategies and outcomes for the PF-BES following this evidence.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
dual-antiplatelet-therapy-strategies-and-clinical-outcomes-for-a-polymer-free-bi.pdf
Accesso riservato
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
746.83 kB
Formato
Adobe PDF
|
746.83 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
